Association of SCLC promoter methylation with gene expression and with drug sensitivity are in agreement with the findings of He et al. [82], who showed that increased methylation of the SLFN11 promoter in colorectal cancer cell lines and primary tumors led to downregulation of SLFN11 expression, increased tumor resistance to cisplatin, and decreased the 5-year overall patient survival and 5-year progression-free survival. Here, SLFN11 is linked to colorectal cancer.